81529-60-4

Usage

InChI:InChI=1/C12H14N2S/c1-7-4-8(2)11(9(3)5-7)10-6-15-12(13)14-10/h4-6H,1-3H3,(H2,13,14)

Upstream product

• 50690-12-5 2-chloro-1-(2,4,6-trimethyl-phenyl)-ethanone 
• 17356-08-0 thiourea 
• 4225-92-7 2-bromo-1-(2,4,6-trimethylphenyl)ethanone 
• 1667-01-2 2,4,6-Trimethylacetophenone 
• 108-67-8 1,3,5-trimethyl-benzene 

Downstream Products

• 1134986-18-7 thiazole-2-carboxylic acid [4-(2,4,6-trimethylphenyl)thiazol-2-yl]amide 
• 745022-89-3 pyrazine-2-carboxylic acid [4-(2,4,6-trimethylphenyl)thiazol-2-yl]amide 
• 1134986-24-5 morpholine-4-carboxylic acid [4-(2,4,6-trimethylphenyl)thiazol-2-yl]amide 
• 950032-53-8 pyridine-2-carboxylic acid [4-(2,4,6-trimethylphenyl)thiazol-2-yl]amide 
• 950078-55-4 N-[4-(2,4,6-trimethylphenyl)thiazol-2-yl]nicotinamide 
• 1001753-24-7 N-[4-(2,4,6-trimethylphenyl)-2-thiazolyl]-benzamide 
• 1134985-98-0 2-methoxy-N-[4-(2,4,6-trimethylphenyl)thiazol-2-yl]benzamide 
• 872456-21-8 2-trifluoromethyl-N-[4-(2,4,6-trimethylphenyl)thiazol-2-yl]benzamide 
• 849513-58-2 N-(4-mesitylthiazol-2-yl)isonicotinamide 
• 1334921-00-4 N-(4-mesitylthiazol-2-yl)-2-(pyridin-4-yl)acetamide 
• 313252-23-2 4-cyano-N-(4-mesitylthiazol-2-yl)benzamide 
• 1334920-60-3 4-[(4-mesitylthiazol-2-yl)carbamoyl]pyridine 1-oxide 
• 313366-31-3 4-[(4-mesitylthiazol-2-yl)carbamoyl]pyridine 1-oxide 

Relevant academic research and scientific papers

Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents

The emergence of antibiotic resistant pathogens is an ongoing main problem in the therapy of bacterial infections. In order to develop promising antitubercular and antibacterial lead compounds, we designed and synthesized a new series of derivatives of 2-aminothiazole conjugated nitrofuran with activities against both Mycobacterium tuberculosis and Staphylococcus aureus. Eight compounds 12e, 12k, 12l, 12m, 18a, 18d, 18e, and 18j emerged as promising antitubercular agents. Structure–activity relationships (SARs) were discussed and showed that the derivatives substituted at the position-3 of benzene of 5-nitro-N-(4-phenylthiazol-2-yl)furan-2-carboxamide exhibited superior potency. The most potent compound 18e, substituted with benzamide at this position, displayed minimum inhibitory concentrations (MICs) of 0.27 μg/mL against Mtb H37Ra and 1.36 μg/mL against S. aureus. Furthermore, compound 18e had no obvious cytotoxicity to normal Vero cells (IC50= 50.2 μM). The results suggest that the novel scaffolds of aminothiazole conjugated nitrofuran would be a promising class of potent antitubercular and antimicrobial agents.

Synthesis and biological evaluation of N-(4-phenylthiazol-2-yl)cinnamamide derivatives as novel potential anti-tumor agents

In this study, a series of novel N-(4-phenylthiazol-2-yl)cinnamamide derivatives (7a-8n) were synthesized and evaluated for their anti-proliferative activities in vitro by MTT assay and a possible antitumor mechanism was also explored. SAR analysis showed that steric effects played an important role on the anti-tumor activity. The most potent analogue 8f showed excellent inhibitions on the K562, Bel7402, A549 and Jurkat cells ranging from sub-micromolar to nanomolar concentration. Compound 8f inhibited Jurkat cells with an IC50 value of 0.035 μM with no apparent toxicity in different non-cancerous cells. Furthermore, it was suggested that the possible mechanism of 8f might be associated with inducing cancer cell apoptosis following flow cytometer analysis and Hoechst 33358 staining assays.

Discovery of 4-aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 inhibitors. Part I: Optimization of in vitro potencies and pharmacokinetic properties

A series of 4-aryl-N-arylcarbonyl-2-aminothiazoles of scaffold 4 was designed and synthesized as Hec1/Nek2 inhibitors. Structural optimization of 4 led to compound 32 bearing C-4′ 4-methoxyphenoxy and 4-(o-fluoropyridyl) carbonyl groups that showed low nanomolar in vitro antiproliferative activity (IC50: 16.3-42.7 nM), high intravenous AUC (64.9 μM·h, 2.0 mg/kg) in SD rats, and significant in vivo antitumor activity (T/C = 32%, 20 mg/kg, IV) in mice bearing human MDA-MB-231 xenografts. Cell responses resulting from Hec1/Nek2 inhibition were observed in cells treated with 32, including a reduced level of Hec1 coimmunoprecipitated with Nek2, degradation of Nek2, mitotic abnormalities, and apoptosis. Compound 32 showed selectivity toward cancer cells over normal phenotype cells and was inactive in a [ 3H]astemizole competitive binding assay for hERG liability screening. Therefore, 32 is as a good lead toward the discovery of a preclinical candidate targeting Hec1/Nek2 interaction.

IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR

Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases

Modulators Of HEC1 Activity And Methods Therefor

Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Especially preferred compounds disrupt Nek2/Hec1 binding and are therefore useful as chemotherapeutic agent for neoplastic diseases.

Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues

High expression in cancer 1 (Hec1) is an oncogene overly expressed in many human cancers. Small molecule inhibitor of Nek2/Hec1 (INH) targeting the Hec1 and its regulator, Nek2, in the mitotic pathway, was identified to inactivate Hec1/Nek2 function media